vs
西蒙地产集团（ELS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是西蒙地产集团的1.6倍（$622.0M vs $397.6M），Royalty Pharma plc同比增速更快（4.8% vs 2.7%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.3%）
西蒙地产集团是美国头部房地产投资信托企业，投资范围涵盖购物中心、奥特莱斯及社区生活中心等商业地产业态，是美国规模最大的购物中心持有方，总部位于印第安纳州印第安纳波利斯，截至2024年12月末共持有232处物业权益。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ELS vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$397.6M
营收增速更快
RPRX
高出2.1%
2.7%
两年增速更快
RPRX
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $397.6M | $622.0M |
| 净利润 | — | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | — | 62.4% |
| 净利率 | — | 34.4% |
| 营收同比 | 2.7% | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $0.56 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELSRPRX
| Q1 26 | $397.6M | — | ||
| Q4 25 | $373.9M | $622.0M | ||
| Q3 25 | $393.3M | $609.3M | ||
| Q2 25 | $376.9M | $578.7M | ||
| Q1 25 | $387.3M | $568.2M | ||
| Q4 24 | $372.3M | $593.6M | ||
| Q3 24 | $387.3M | $564.7M | ||
| Q2 24 | $380.0M | $537.3M |
净利润ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | $103.8M | $214.2M | ||
| Q3 25 | $100.4M | $288.2M | ||
| Q2 25 | $83.5M | $30.2M | ||
| Q1 25 | $114.4M | $238.3M | ||
| Q4 24 | $100.6M | $208.2M | ||
| Q3 24 | $86.9M | $544.0M | ||
| Q2 24 | $82.1M | $102.0M |
营业利润率ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 26.5% | 62.4% | ||
| Q3 25 | 25.1% | 70.1% | ||
| Q2 25 | 22.3% | 36.3% | ||
| Q1 25 | 28.3% | 94.0% | ||
| Q4 24 | 27.2% | 60.9% | ||
| Q3 24 | 21.4% | — | ||
| Q2 24 | 21.5% | 50.2% |
净利率ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 27.8% | 34.4% | ||
| Q3 25 | 25.5% | 47.3% | ||
| Q2 25 | 22.2% | 5.2% | ||
| Q1 25 | 29.5% | 41.9% | ||
| Q4 24 | 27.0% | 35.1% | ||
| Q3 24 | 22.4% | 96.3% | ||
| Q2 24 | 21.6% | 19.0% |
每股收益（稀释后）ELSRPRX
| Q1 26 | $0.56 | — | ||
| Q4 25 | $0.52 | $0.49 | ||
| Q3 25 | $0.50 | $0.67 | ||
| Q2 25 | $0.42 | $0.07 | ||
| Q1 25 | $0.57 | $0.55 | ||
| Q4 24 | $0.51 | $0.46 | ||
| Q3 24 | $0.44 | $1.21 | ||
| Q2 24 | $0.42 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.8B | $9.7B |
| 总资产 | $5.7M | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B |
总债务ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $3.2B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益ELSRPRX
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $9.7B | ||
| Q3 25 | $1.8B | $9.6B | ||
| Q2 25 | $1.7B | $9.5B | ||
| Q1 25 | $1.7B | $9.8B | ||
| Q4 24 | $1.7B | $10.3B | ||
| Q3 24 | $1.4B | $10.3B | ||
| Q2 24 | $1.4B | $9.8B |
总资产ELSRPRX
| Q1 26 | $5.7M | — | ||
| Q4 25 | $5.7B | $19.6B | ||
| Q3 25 | $5.7B | $19.3B | ||
| Q2 25 | $5.7B | $18.3B | ||
| Q1 25 | $5.6B | $17.6B | ||
| Q4 24 | $5.6B | $18.2B | ||
| Q3 24 | $5.6B | $18.0B | ||
| Q2 24 | $5.6B | $17.7B |
负债/权益比ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 1.91× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.84× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | $571.1M | $827.1M | ||
| Q3 25 | $147.0M | $702.6M | ||
| Q2 25 | $131.3M | $364.0M | ||
| Q1 25 | $193.4M | $596.1M | ||
| Q4 24 | $596.7M | $742.5M | ||
| Q3 24 | $149.5M | $703.6M | ||
| Q2 24 | $143.1M | $658.2M |
自由现金流ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | $334.1M | — | ||
| Q3 25 | $75.7M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $148.2M | — | ||
| Q4 24 | $355.4M | — | ||
| Q3 24 | $91.1M | — | ||
| Q2 24 | $80.6M | — |
自由现金流率ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 89.4% | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 19.1% | — | ||
| Q1 25 | 38.3% | — | ||
| Q4 24 | 95.5% | — | ||
| Q3 24 | 23.5% | — | ||
| Q2 24 | 21.2% | — |
资本支出强度ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 63.4% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 11.7% | — | ||
| Q4 24 | 64.8% | — | ||
| Q3 24 | 15.1% | — | ||
| Q2 24 | 16.5% | — |
现金转化率ELSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 5.50× | 3.86× | ||
| Q3 25 | 1.46× | 2.44× | ||
| Q2 25 | 1.57× | 12.06× | ||
| Q1 25 | 1.69× | 2.50× | ||
| Q4 24 | 5.93× | 3.57× | ||
| Q3 24 | 1.72× | 1.29× | ||
| Q2 24 | 1.74× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELS
| Rental income | $339.0M | 85% |
| Other | $37.2M | 9% |
| Annual membership subscriptions | $18.3M | 5% |
| Membership upgrade revenue | $3.1M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
